ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 662

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus

Brooke Williams1, Bridget Muckian 1, Claire Dykas 2, Christine Peschken 3, Richard Furie 4, Elena Massarotti 5, Vanja sikirica 6, Steven Gilbert 7, Martin Hodge 7 and Peter Lipsky 8, 1AMPEL BioSolutions, Charlottesville, VA, 2AmpelBioSolutions, Charlottesville, VA, 3University of Manitoba, Winnepeg, Canada, 4Northwell Health, Great Neck, NY, 5Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 6Pfizer, Boston, MA, 7Pfizer, Boston, 8AMPEL BioSolutions, LLC, Charlottesville, VA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: data collection and patient health, patient outcomes, Patient questionnaires, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to medication. However, in most circumstances, PRO information is collected only intermittently and usually at the point of care or treatment. The development of mobile technology to collect PRO data electronically (ePRO) provided the opportunity to acquire this information more frequently, in real time, and in the person’s normal environment. The objective of the research was to develop a smart phone application (app) and test its utility to collect ePRO information in people with systemic lupus erythematosus (SLE).

Methods: A smart phone app was developed that collects data from a number of PRO instruments, including FACIT-F (fatigue), SF-36 (health-related quality of life) and patient global assessment (PtGA). People living with SLE were involved in the initial development and evaluation of the acceptability of the app. To test to utility of this app, a multi-center clinical study (VALUE, NCT03142711) was carried out in collaboration with people with SLE, in whom ePRO information was collected with the app daily (PtGA) or weekly (FACIT-F and SF-36) in the person’s environment and also with the app and a  paper form monthly at the clinical site. Demographic information, compliance and intra-class correlation coefficients between information collected with the app and using a paper form at the clinical site were assessed.

Results: Of the 80 people enrolled in this study, 91.3% were women; 57.5%, 16.3% and 17.5% identified themselves as of European, African or Asian ancestry, respectively. The mean age was 42.6 years and the mean duration of education was 15.6 years. Overall compliance with completing the ePRO instruments with the app at the scheduled time was 88%. To determine the consistency of information collected with the app, PRO instruments were completed on three occasions: a) in standard fashion using a paper form and b) using the app, separated by an interruption at the clinical site. The mean (SD) PtGA, FACIT-F and SF-36 Physical Functioning and General Health scores at baseline, month 1 and month 2  using the app and paper forms were similar (Figure 1). The Intraclass Correlation Coefficient (ICC) and 90%CI were 0.97 (0.96-0.98), 0.96 (0.94-0.07) and 0.95(0.93-0.97) at the three time points, respectively for the PtGA; 0.94(0.91-0.96), 0.96(0.95-0.98) and 0.96(0.94-0.97), respectively for the FACIT-F instrument; and , 0.96(0.94-0.97), 0.94(0.91-0.96) and 0.96 (0.94-0.97) for the 3 time points, respectively for the SF-36 Physical Functioning score.

Conclusion: Compliance with completion of ePROs using a mobile app was high and the content collected with the app conformed with that collected using a paper form. Since compliance with the use of a mobile app to collect ePRO information and the consistency of the information obtained compared to that obtained using a paper form were high, the app affords the potential opportunity to acquire frequent and highly reliable information about the impact of disease and response to medication in individuals with SLE.  

Figure 1


Disclosure: B. Williams, None; B. Muckian, None; C. Dykas, None; C. Peschken, None; R. Furie, Biogen, 5, GlaxoSmithKline, 2, 5, UCB Pharma, 2, 5; E. Massarotti, Exagen, 2; V. sikirica, Pfizer, 3; S. Gilbert, Pfizer, 3; M. Hodge, Pfizer, 3; P. Lipsky, Horizon, 5, Janssen Research & Development, LLC, 2.

To cite this abstract in AMA style:

Williams B, Muckian B, Dykas C, Peschken C, Furie R, Massarotti E, sikirica V, Gilbert S, Hodge M, Lipsky P. Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/utility-of-a-mobile-phone-based-application-to-collect-patient-reported-outcome-information-from-people-living-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-a-mobile-phone-based-application-to-collect-patient-reported-outcome-information-from-people-living-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology